Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment

International Journal of Molecular Sciences

Volumn 18, Issue 7, 2017, Pages

  Bignucolo, Alessia ^a   De Mattia, Elena ^a   Cecchin, Erika ^a   Roncato, Rossana ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Anti EGFR agents; Antiangiogenic molecules; Inflammation; Metastatic colorectal cancer; Pharmacogenomics; Rat sarcoma oncogene (RAS); Somatic mutation; Targeted agents; Vascular endothelial growth factor (VEGF)

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAMUCIRUMAB; REGORAFENIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL PRACTICE; COLORECTAL CANCER; GENE MUTATION; GENETIC MARKER; HUMAN; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SOMATIC MUTATION; TREATMENT OUTCOME; TUMOR RESISTANCE; BIOLOGICAL MODEL; COLORECTAL TUMOR; GENETICS; PHARMACOGENETICS;

COLORECTAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 85024865200     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18071522     Document Type: Review

References (101)

1. International Association of Cancer Registries. Available online: http://iicc.iarc.fr/(accessed on 29 May 2015).
2. Marley, A.R.; Nan, H. Epidemiology of colorectal cancer. Int. J. Mol. Epidemiol. Genet. 2016, 7, 105–114. [PubMed]
3. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30. [CrossRef] [PubMed]
4. Van Loon, K.; Venook, A.P. Adjuvant treatment of colon cancer: What is next? Curr. Opin. Oncol. 2011, 23, 403–409.
5. Price, T.J.; Segelov, E.; Burge, M.; Haller, D.G.; Ackland, S.P.; Tebbutt, N.C.; Karapetis, C.S.; Pavlakis, N.; Sobrero, A.F.; Cunningham, D.; et al. Current opinion on optimal treatment for colorectal cancer. Expert. Rev. Anticancer Ther. 2013, 13, 597–611. [CrossRef] [PubMed]
6. Sanz-Garcia, E.; Grasselli, J.; Argiles, G.; Elez, M.E.; Tabernero, J. Current and advancing treatments for metastatic colorectal cancer. Expert. Opin. Biol. Ther. 2016, 16, 93–110. [CrossRef] [PubMed]
7. Marcus, L.; Lemery, S.J.; Khasar, S.; Wearne, E.; Helms, W.S.; Yuan, W.; He, K.; Cao, X.; Yu, J.; Zhao, H.; et al. FDA Approval Summary: TAS-102. Clin. Cancer Res. 2017, 23, 2924–2927. [CrossRef] [PubMed]
8. Longo-Munoz, F.; Argiles, G.; Tabernero, J.; Cervantes, A.; Gravalos, C.; Pericay, C.; Gil-Calle, S.; Mizuguchi, H.; Carrato-Mena, A.; Limon, M.L.; et al. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: Results of a subgroup analysis of the phase 3 RECOURSE trial. Clin. Transl. Oncol. 2017, 19, 227–235. [CrossRef] [PubMed]
9. Lynch, D.; Murphy, A. The emerging role of immunotherapy in colorectal cancer. Ann. Transl. Med. 2016, 4, 305. [CrossRef] [PubMed]
10. De Mattia, E.; Cecchin, E.; Toffoli, G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resist. Update 2015, 20, 39–70. [CrossRef] [PubMed]
11. Fiala, O.; Buchler, T.; Mohelnikova-Duchonova, B.; Melichar, B.; Matejka, V.M.; Holubec, L.; Kulhankova, J.; Bortlicek, Z.; Bartouskova, M.; Liska, V.; et al. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour. Biol. 2016, 37, 6823–6830. [CrossRef] [PubMed]
12. Cremolini, C.; Loupakis, F.; Antoniotti, C.; Lupi, C.; Sensi, E.; Lonardi, S.; Mezi, S.; Tomasello, G.; Ronzoni, M.; Zaniboni, A.; et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015, 16, 1306–1315. [CrossRef]
13. Nakayama, I.; Shinozaki, E.; Matsushima, T.; Wakatsuki, T.; Ogura, M.; Ichimura, T.; Ozaka, M.; Takahari, D.; Suenaga, M.; Chin, K.; et al. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer 2017, 17, 38. [CrossRef] [PubMed]
14. Garde, N.J.; Jantus-Lewintre, E.; Gil-Raga, M.; Evgenyeva, E.; Macia, E.S.; Llombart-Cussac, A.; Camps, H.C. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Mol. Clin. Oncol. 2017, 6, 403–408.
15. Renaud, S.; Schaeffer, M.; Falcoz, P.E.; Seitlinger, J.; Romain, B.; Voegeli, A.C.; Legrain, M.; Reeb, J.; Santelmo, N.; Rohr, S.; et al. Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutationsdagger. Eur. J. Cardiothorac. Surg. 2017, 51, 255–262. [PubMed]
16. Tabernero, J.; Takayuki, Y.; Cohn, A.L. Correction to Lancet Oncol 2015; 16: 499–508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015, 16, e262. [PubMed]
17. Adenis, A.; de la Fouchardiere, C.; Paule, B.; Burtin, P.; Tougeron, D.; Wallet, J.; Dourthe, L.M.; Etienne, P.L.; Mineur, L.; Clisant, S.; et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBACCA) nested within a compassionate use program. BMC. Cancer 2016, 16, 412.
18. Loaiza-Bonilla, A.; Jensen, C.E.; Shroff, S.; Furth, E.; Bonilla-Reyes, P.A.; Deik, A.F.; Morrissette, J. KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. Cureus 2016, 8, e478. [CrossRef] [PubMed]
19. Lambrechts, D.; Thienpont, B.; Thuillier, V.; Sagaert, X.; Moisse, M.; Peuteman, G.; Pericay, C.; Folprecht, G.; Zalcberg, J.; Zilocchi, C.; et al. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. Br. J. Cancer 2015, 113, 1027–1034. [CrossRef] [PubMed]
20. Obermannova, R.; Van Custem, E.; Yoshino, T.; Bodoky, G.; Prausova, J.; Garcia-Carbonero, R.; Ciuleanu, T.; Garcia, A.P.; Portnoy, D.; Cohn, A.; et al. Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann. Oncol. 2016, 27, 2082–2090. [CrossRef] [PubMed]
21. Lim, Y.H.; Odell, I.D.; Ko, C.J.; Choate, K.A. Somatic p.T771R KDR (VEGFR2) Mutation Arising in a Sporadic Angioma During Ramucirumab Therapy. JAMA Dermatol. 2015, 151, 1240–1243. [CrossRef] [PubMed]
22. Nakamura, M.; Aoyama, T.; Ishibashi, K.; Tsuji, A.; Takinishi, Y.; Shindo, Y.; Sakamoto, J.; Oba, K.; Mishima, H. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). Cancer Chemother. Pharmacol. 2017, 79, 29–36. [CrossRef] [PubMed]
23. Segelov, E.; Waring, P.; Desai, J.; Wilson, K.; Gebski, V.; Thavaneswaran, S.; Elez, E.; Underhill, C.; Pavlakis, N.; Chantrill, L.; et al. ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC. Cancer 2016, 16, 339. [CrossRef] [PubMed]
24. Osumi, H.; Shinozaki, E.; Osako, M.; Kawazoe, Y.; Oba, M.; Misaka, T.; Goto, T.; Kamo, H.; Suenaga, M.; Kumekawa, Y.; et al. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Mol. Clin. Oncol. 2015, 3, 1053–1057. [CrossRef] [PubMed]
25. Kim, T.W.; Elme, A.; Kusic, Z.; Park, J.O.; Udrea, A.A.; Kim, S.Y.; Ahn, J.B.; Valencia, R.V.; Krishnan, S.; Bilic, A.; et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br. J. Cancer 2016, 115, 1206–1214. [CrossRef] [PubMed]
26. Pietrantonio, F.; Petrelli, F.; Coinu, A.; Di, B.M.; Borgonovo, K.; Maggi, C.; Cabiddu, M.; Iacovelli, R.; Bossi, I.; Lonati, V.; et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur. J. Cancer 2015, 51, 587–594. [CrossRef] [PubMed]
27. Sorich, M.J.; Wiese, M.D.; Rowland, A.; Kichenadasse, G.; McKinnon, R.A.; Karapetis, C.S. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann. Oncol. 2015, 26, 13–21. [CrossRef] [PubMed]
28. Therkildsen, C.; Bergmann, T.K.; Henrichsen-Schnack, T.; Ladelund, S.; Nilbert, M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol. 2014, 53, 852–864. [CrossRef] [PubMed]
29. Huang, L.; Liu, Z.; Deng, D.; Tan, A.; Liao, M.; Mo, Z.; Yang, X. Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: A meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch. Med. Sci. 2014, 10, 1–9. [CrossRef] [PubMed]
30. Peeters, M.; Oliner, K.S.; Price, T.J.; Cervantes, A.; Sobrero, A.F.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin. Cancer Res. 2015, 21, 5469–5479. [CrossRef] [PubMed]
31. Ohhara, Y.; Fukuda, N.; Takeuchi, S.; Honma, R.; Shimizu, Y.; Kinoshita, I.; Dosaka-Akita, H. Role of targeted therapy in metastatic colorectal cancer. World J. Gastrointest. Oncol. 2016, 8, 642–655. [CrossRef] [PubMed]
32. Zhou, M.; Yu, P.; Qu, J.; Chen, Y.; Zhou, Y.; Fu, L.; Zhang, J. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis. Cell. Physiol. Biochem. 2016, 40, 361–369. [CrossRef] [PubMed]
33. Lee, J.J.; Chu, E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin. Colorectal Cancer 2014, 13, 135–144. [CrossRef] [PubMed]
34. Grothey, A.; Van Custem, E.; Sobrero, A.; Siena, S.; Falcone, A.; Ychou, M.; Humblet, Y.; Bouche, O.; Mineur, L.; Barone, C.; et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381, 303–312. [CrossRef]
35. Li, J.; Qin, S.; Xu, R.; Yau, T.C.; Ma, B.; Pan, H.; Xu, J.; Bai, Y.; Chi, Y.; Wang, L.; et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015, 16, 619–629. [CrossRef]
36. Van Custem, E.; Tabernero, J.; Lakomy, R.; Prenen, H.; Prausova, J.; Macarulla, T.; Ruff, P.; van Hazel, G.A.; Moiseyenko, V.; Ferry, D.; et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012, 30, 3499–3506.
37. Douillard, J.Y.; Oliner, K.S.; Siena, S.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J.; et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013, 369, 1023–1034. [CrossRef] [PubMed]
38. Lievre, A.; Bachet, J.B.; Boige, V.; Cayre, A.; Le, C.D.; Buc, E.; Ychou, M.; Bouche, O.; Landi, B.; Louvet, C.; et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 2008, 26, 374–379. [CrossRef] [PubMed]
39. Giusti, R.M.; Shastri, K.A.; Cohen, M.H.; Keegan, P.; Pazdur, R. FDA drug approval summary: Panitumumab (Vectibix). Oncologist 2007, 12, 577–583. [CrossRef] [PubMed]
40. Sickmier, E.A.; Kurzeja, R.J.; Michelsen, K.; Vazir, M.; Yang, E.; Tasker, A.S. The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance. PLoS ONE. 2016, 11, e0163366. [CrossRef] [PubMed]
41. Bertotti, A.; Papp, E.; Jones, S.; Adleff, V.; Anagnostou, V.; Lupo, B.; Sausen, M.; Phallen, J.; Hruban, C.A.; Tokheim, C.; et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015, 526, 263–267. [CrossRef] [PubMed]
42. Leslie, M. Potential Therapy for Refractory Colon Cancer. Cancer Discov. 2016, 6, 336–337. [PubMed]
43. Van Emburgh, B.O.; Arena, S.; Siravegna, G.; Lazzari, L.; Crisafulli, G.; Corti, G.; Mussolin, B.; Baldi, F.; Buscarino, M.; Bartolini, A.; et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat. Commun. 2016, 7, 13665. [CrossRef] [PubMed]
44. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341–354. [CrossRef] [PubMed]
45. Oddo, D.; Sennott, E.M.; Barault, L.; Valtorta, E.; Arena, S.; Cassingena, A.; Filiciotto, G.; Marzolla, G.; Elez, E.; van Geel, R.M.; et al. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Res. 2016, 76, 4504–4515. [CrossRef] [PubMed]
46. Richman, S.D.; Southward, K.; Chambers, P.; Cross, D.; Barrett, J.; Hemmings, G.; Taylor, M.; Wood, H.; Hutchins, G.; Foster, J.M.; et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J. Pathol. 2016, 238, 562–570. [CrossRef] [PubMed]
47. Parikh, A.; Atreya, C.; Korn, W.M.; Venook, A.P. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. J. Natl. Compr. Canc. Netw. 2017, 15, 3–8. [CrossRef] [PubMed]
48. Sartore-Bianchi, A.; Trusolino, L.; Martino, C.; Bencardino, K.; Lonardi, S.; Bergamo, F.; Zagonel, V.; Leone, F.; Depetris, I.; Martinelli, E.; et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016, 17, 738–746. [CrossRef]
49. Rubinson, D.A.; Hochster, H.S.; Ryan, D.P.; Wolpin, B.M.; McCleary, N.J.; Abrams, T.A.; Chan, J.A.; Iqbal, S.; Lenz, H.J.; Lim, D.; et al. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Investig. New Drugs 2014, 32, 113–122. [CrossRef] [PubMed]
50. Kloth, M.; Ruesseler, V.; Engel, C.; Koenig, K.; Peifer, M.; Mariotti, E.; Kuenstlinger, H.; Florin, A.; Rommerscheidt-Fuss, U.; Koitzsch, U.; et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Gut 2016, 65, 1296–1305. [CrossRef] [PubMed]
51. Aung, K.L.; Stockley, T.L.; Serra, S.; Kamel-Reid, S.; Bedard, P.L.; Siu, L.L. Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Cold Spring Harb. Mol. Case. Stud. 2016, 2, a001016. [CrossRef] [PubMed]
52. Schoeberl, B.; Faber, A.C.; Li, D.; Liang, M.C.; Crosby, K.; Onsum, M.; Burenkova, O.; Pace, E.; Walton, Z.; Nie, L.; et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010, 70, 2485–2494. [CrossRef] [PubMed]
53. Breuleux, M. Role of heregulin in human cancer. Cell. Mol. Life Sci. 2007, 64, 2358–2377. [CrossRef] [PubMed]
54. Lee, Y.C.; Michael, M.; Zalcberg, J.R. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer. Expert. Opin. Investig. Drugs 2015, 24, 1307–1320. [CrossRef] [PubMed]
55. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/(accessed on 29 May 2015).
56. Dienstmann, R.; Patnaik, A.; Garcia-Carbonero, R.; Cervantes, A.; Benavent, M.; Rosello, S.; Tops, B.B.; van der Post, R.S.; Argiles, G.; Skartved, N.J.; et al. Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discov. 2015, 5, 598–609. [CrossRef] [PubMed]
57. Sanchez-Martin, F.J.; Bellosillo, B.; Gelabert-Baldrich, M.; Dalmases, A.; Canadas, I.; Vidal, J.; Martinez, A.; Argiles, G.; Siravegna, G.; Arena, S.; et al. The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. Clin. Cancer Res. 2016, 22, 3260–3267. [CrossRef] [PubMed]
58. Arena, S.; Siravegna, G.; Mussolin, B.; Kearns, J.D.; Wolf, B.B.; Misale, S.; Lazzari, L.; Bertotti, A.; Trusolino, L.; Adjei, A.A.; et al. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci. Transl. Med. 2016, 8, 324ra14. [CrossRef] [PubMed]
59. Kearns, J.D.; Bukhalid, R.; Sevecka, M.; Tan, G.; Gerami-Moayed, N.; Werner, S.L.; Kohli, N.; Burenkova, O.; Sloss, C.M.; King, A.M.; et al. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Mol. Cancer Ther. 2015, 14, 1625–1636. [CrossRef] [PubMed]
60. Deming, D.A.; Cavalcante, L.L.; Lubner, S.J.; Mulkerin, D.L.; LoConte, N.K.; Eickhoff, J.C.; Kolesar, J.M.; Fioravanti, S.; Greten, T.F.; Compton, K.; et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest. New Drugs 2016, 34, 168–175. [CrossRef] [PubMed]
61. Corcoran, R.B.; Atreya, C.E.; Falchook, G.S.; Kwak, E.L.; Ryan, D.P.; Bendell, J.C.; Hamid, O.; Messersmith, W.A.; Daud, A.; Kurzrock, R.; et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J. Clin. Oncol. 2015, 33, 4023–4031. [CrossRef] [PubMed]
62. Orlandi, A.; Calegari, A.; Inno, A.; Berenato, R.; Caporale, M.; Niger, M.; Bossi, I.; Di, B.M.; de, B.F.; Pietrantonio, F. BRAF in metastatic colorectal cancer: The future starts now. Pharmacogenomics. 2015, 16, 2069–2081. [CrossRef] [PubMed]
63. Williams, C.B.; McMahon, C.; Ali, S.M.; Abramovitz, M.; Williams, K.A.; Klein, J.; McKean, H.; Yelensky, R.; George, T.J., Jr.; Elvin, J.A. et al. A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. Onco. Targets. Ther. 2015, 8, 3561–3564. [PubMed]
64. Kopetz, S.; Desai, J.; Chan, E.; Hecht, J.R.; O’Dwyer, P.J.; Maru, D.; Morris, V.; Janku, F.; Dasari, A.; Chung, W.; et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J. Clin. Oncol. 2015, 33, 4032–4038. [CrossRef] [PubMed]
65. Hong, D.S.; Morris, V.K.; El, O.B.; Sorokin, A.V.; Janku, F.; Fu, S.; Overman, M.J.; Piha-Paul, S.; Subbiah, V.; Kee, B.; et al. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016, 6, 1352–1365. [CrossRef] [PubMed]
66. Yaeger, R.; Cercek, A.; O'Reilly, E.M.; Reidy, D.L.; Kemeny, N.; Wolinsky, T.; Capanu, M.; Gollub, M.J.; Rosen, N.; Berger, M.F.; et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin. Cancer Res. 2015, 21, 1313–1320. [CrossRef] [PubMed]
67. Van Geel, R.M.J.M.; Tabernero, J.; Elez, E.; Bendell, J.C.; Spreafico, A.; Schuler, M.; Yoshino, T.; Delord, J.P.; Yamada, Y.; Lolkema, M.P.; et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017, 7, 610–619. [CrossRef] [PubMed]
68. Zhang, J.; Lu, B.; Liu, D.; Shen, R.; Yan, Y.; Yang, L.; Zhang, M.; Zhang, L.; Cao, G.; Cao, H.; et al. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol. Ther. 2016, 17, 199–207. [CrossRef] [PubMed]
69. Tang, Z.; Yuan, X.; Du, R.; Cheung, S.H.; Zhang, G.; Wei, J.; Zhao, Y.; Feng, Y.; Peng, H.; Zhang, Y.; et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol. Cancer Ther. 2015, 14, 2187–2197. [CrossRef] [PubMed]
70. Dasari, A.; Messersmith, W.A. New strategies in colorectal cancer: Biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin. Cancer Res. 2010, 16, 3811–3818. [CrossRef] [PubMed]
71. Mao, C.; Yang, Z.Y.; Hu, X.F.; Chen, Q.; Tang, J.L. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Ann. Oncol. 2012, 23, 1518–1525. [CrossRef] [PubMed]
72. Rodon, J.; Brana, I.; Siu, L.L.; De Jonge, M.J.; Homji, N.; Mills, D.; Di, T.E.; Sarr, C.; Trandafir, L.; Massacesi, C.; et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Investig. New Drugs 2014, 32, 670–681. [CrossRef] [PubMed]
73. Fernandes, M.S.; Melo, S.; Velho, S.; Carneiro, P.; Carneiro, F.; Seruca, R. Specific inhibition of p110alpha subunit of PI3K: Putative therapeutic strategy for KRAS mutant colorectal cancers. Oncotarget. 2016, 7, 68546–68558. [PubMed]
74. Jifu, E.; Xing, J.; Gong, H.; He, J.; Zhang, W. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. Tumour. Biol. 2015, 36, 1091–1097.
75. Fang, D.D.; Zhang, C.C.; Gu, Y.; Jani, J.P.; Cao, J.; Tsaparikos, K.; Yuan, J.; Thiel, M.; Jackson-Fisher, A.; Zong, Q.; et al. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. PLoS ONE 2013, 8, e67258. [CrossRef] [PubMed]
76. Hanna, D.L.; Lenz, H.J. Novel therapeutics in metastatic colorectal cancer: Molecular insights and pharmacogenomic implications. Expert Rev. Clin. Pharmacol. 2016, 9, 1091–1108. [CrossRef] [PubMed]
77. Konda, B.; Shum, H.; Rajdev, L. Anti-angiogenic agents in metastatic colorectal cancer. World J. Gastrointest. Oncol. 2015, 7, 71–86. [CrossRef] [PubMed]
78. Xu, R.S.L.; Wang, K.; Wu, G.; Shi, C.; Ding, K.; Lin, L.; Wang, J.; Xiong, J.; Wu, C.; Li, J.; et al. A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer. J. Clin. Oncol. 2015, 33, 513. [CrossRef]
79. Van Custem, E.; Prenen, H.; D'Haens, G.; Bennouna, J.; Carrato, A.; Ducreux, M.; Bouche, O.; Sobrero, A.; Latini, L.; Staines, H.; et al. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Ann. Oncol. 2015, 26, 2085–2091.
80. Van Custem, E.; Yoshino, T.; Hocke, J.; Oum’Hamed, Z.; Studeny, M.; Tabernero, J. Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment. Clin. Colorectal Cancer 2016, 15, 91–94.
81. Hecht, J.R.; Trarbach, T.; Hainsworth, J.D.; Major, P.; Jager, E.; Wolff, R.A.; Lloyd-Salvant, K.; Bodoky, G.; Pendergrass, K.; Berg, W.; et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J. Clin. Oncol. 2011, 29, 1997–2003. [CrossRef] [PubMed]
82. Van Custem, E.; Bajetta, E.; Valle, J.; Kohne, C.H.; Hecht, J.R.; Moore, M.; Germond, C.; Berg, W.; Chen, B.L.; Jalava, T.; et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J. Clin. Oncol. 2011, 29, 2004–2010.
83. Carrato, A.; Swieboda-Sadlej, A.; Staszewska-Skurczynska, M.; Lim, R.; Roman, L.; Shparyk, Y.; Bondarenko, I.; Jonker, D.J.; Sun, Y.; De la Cruz, J.A.; et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial. J. Clin. Oncol. 2013, 31, 1341–1347. [CrossRef] [PubMed]
84. Samalin, E.; Bouche, O.; Thezenas, S.; Francois, E.; Adenis, A.; Bennouna, J.; Taieb, J.; Desseigne, F.; Seitz, J.F.; Conroy, T.; et al. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: A multicentre Phase I/II trial. Br. J. Cancer 2014, 110, 1148–1154. [CrossRef] [PubMed]
85. Tabernero, J.; Garcia-Carbonero, R.; Cassidy, J.; Sobrero, A.; Van Custem, E.; Kohne, C.H.; Tejpar, S.; Gladkov, O.; Davidenko, I.; Salazar, R.; et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial. Clin. Cancer Res. 2013, 19, 2541–2550. [CrossRef] [PubMed]
86. Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. J. Clin. Oncol. 2014, 32, 579–586. [CrossRef] [PubMed]
87. Misale, S.; Yaeger, R.; Hobor, S.; Scala, E.; Janakiraman, M.; Liska, D.; Valtorta, E.; Schiavo, R.; Buscarino, M.; Siravegna, G.; et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486, 532–536. [CrossRef] [PubMed]
88. Diehl, F.; Li, M.; Dressman, D.; He, Y.; Shen, D.; Szabo, S.; Diaz, L.A., Jr.; Goodman, S.N.; David, K.A.; Juhl, H.; et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. USA 2005, 102, 16368–16373. [CrossRef] [PubMed]
89. Higgins, M.J.; Jelovac, D.; Barnathan, E.; Blair, B.; Slater, S.; Powers, P.; Zorzi, J.; Jeter, S.C.; Oliver, G.R.; Fetting, J.; et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 2012, 18, 3462–3469. [CrossRef] [PubMed]
90. Chen, W.W.; Balaj, L.; Liau, L.M.; Samuels, M.L.; Kotsopoulos, S.K.; Maguire, C.A.; Loguidice, L.; Soto, H.; Garrett, M.; Zhu, L.D.; et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol. Ther. Nucleic Acids 2013, 2, e109. [CrossRef] [PubMed]
91. Kinde, I.; Wu, J.; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. USA 2011, 108, 9530–9535. [CrossRef] [PubMed]
92. El Massaoudi, S.; Mouliere, F.; Du, M.S.; Bascoul-Mollevi, C.; Gillet, B.; Nouaille, M.; Fiess, C.; Crapez, E.; Bibeau, F.; Theillet, C.; et al. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin. Cancer Res. 2016, 22, 3067–3077. [CrossRef] [PubMed]
93. Spindler, K.L.; Pallisgaard, N.; Andersen, R.F.; Brandslund, I.; Jakobsen, A. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS ONE. 2015, 10, e0108247. [CrossRef] [PubMed]
94. Tie, J.; Kinde, I.; Wang, Y.; Wong, H.L.; Roebert, J.; Christie, M.; Tacey, M.; Wong, R.; Singh, M.; Karapetis, C.S.; et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 2015, 26, 1715–1722. [CrossRef] [PubMed]
95. Murtaza, M.; Dawson, S.J.; Tsui, D.W.; Gale, D.; Forshew, T.; Piskorz, A.M.; Parkinson, C.; Chin, S.F.; Kingsbury, Z.; Wong, A.S.; et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497, 108–112. [CrossRef] [PubMed]
96. Hutchinson, L. Gastrointestinal cancer: A step closer to combating acquired resistance in CRC. Nat. Rev. Clin. Oncol. 2012, 9, 428. [CrossRef] [PubMed]
97. McLeod, H.L. Cancer pharmacogenomics: Early promise, but concerted effort needed. Science 2013, 339, 1563–1566. [CrossRef] [PubMed]
98. Sadanandam, A.; Lyssiotis, C.A.; Homicsko, K.; Collisson, E.A.; Gibb, W.J.; Wullschleger, S.; Ostos, L.C.; Lannon, W.A.; Grotzinger, C.; Del, R.M.; et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 2013, 19, 619–625. [CrossRef] [PubMed]
99. Mlecnik, B.; Bindea, G.; Angell, H.K.; Maby, P.; Angelova, M.; Tougeron, D.; Church, S.E.; Lafontaine, L.; Fischer, M.; Fredriksen, T.; et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity 2016, 44, 698–711. [CrossRef] [PubMed]
100. U.S. FOOD & DRUG Administration. Available online: http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm (accessed on 29 May 2015).
101. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372, 2509–2520. [CrossRef] [PubMed]